Citations

Clear

305 citation(s) found for "Wan, Yu".

Corrigendum to “Obesity Does Not Increase Complication Rate of Percutaneous Epicardial Access”
Wan, Siu‐Hin , KILLU, AMMARM, Hodge, David O. , Packer, Douglas L. , Mulpuru, Siva K. , Asirvatham, Samuel J. , Munger, Thomas M. , Friedman, Paul A. , Asirvatham, Samuel J , Killu, Ammar M.

Mayo Clinic

Journal of Cardiovascular Electrophysiology | October 1, 2023 | Volume: 25 | Issue: 12 | Pages: 1419-1419

10.1111/jce.12581 Get It

Evaluating skin colour diversity in the validation of scar assessment tools
Garg, Stuti P. , Williams, Tokoya, Taritsa, Iulianna C. , Wan, Rou , Goel, Chirag , Harris, Raiven, Huffman, Kristin, Galiano, Robert D. , Galiano, Robert D

Mayo Clinic

Wound Repair and Regeneration | September 28, 2023 | Volume: 31 | Issue: 6 | Pages: 731-737

10.1111/wrr.13120 | PMID 37768279 Get It

Abstract Across scar studies, there is a lack of dark‐skinned individuals, who have a predisposition for keloid formation, altered pigmentation and poorer quality of life (QOL). There is a need for patients of colour to be included in scar scale development and validation. In this study, we evaluate the racial diversity of patients included in the validation of scar assessment scales. A systematic review was conducted for articles reporting on the validation of a scar assessment tool. Racial, ethnic and Fitzpatrick skin type (FST) data were extracted. Fifteen scar scale validation studies were included. Nine of the studies did not mention FST, race or ethnicity of the patients. Two of the studies that reported FST or race information only included White patients or included no FST V/VI patients: mapping assessment of scars (MAPS) and University of North Carolina ‘4P’. Only four studies included non‐White patients or dark‐skinned patients in the validation of their scar scale: the modified Vancouver Scar Scale (VSS), modified Patient and Observer Scar Assessment Scale (POSAS), acne QOL and SCAR‐Q scales. The patients included in the modified VSS validation were 7% and 13% FST V/VI, 14% African in the modified POSAS and 4.5% FST V/VI in the SCAR‐Q. We highlight the severe lack of diversity in scar scale validation, with only 4 out of 15 studies including dark‐skinned patients. Given the susceptibility of darker‐skinned individuals to have poorer scarring outcomes, it is critical to include patients of colour in the very assessment tools that determine their scar prognosis. Inclusion of patients of colour in scar scale development will improve scar assessment and clinical decision‐making.
Germline Sequencing Analysis to Inform Clinical Gene Panel Testing for Aggressive Prostate Cancer
Saunders, Edward J. , Sheng, Xin , Wan, Peggy , Pooler, Loreall , Xia, Lucy , Chanock, Stephen, Berndt, Sonja I., Patel, Alpa V. , Albanes, Demetrius, Weinstein, Stephanie J. , Gnanapragasam, Vincent J. , Huff, Chad D. , Pomerantz, Mark M., Schmidt, Julie A. , Travis, Ruth C. , Mucci, Lorelei A. , Catàlona, William J. , Marosy, Beth, Hetrick, Kurt N. , Doheny, Kimberly F. , MacInnis, Robert J. , Eeles, Rosalind A. , Kote‐Jarai, Zsofia , Haiman, Christopher A. , Eeles, Rosalind A , Travis, Ruth C , Maclnnis, Robert , Darst, Burcu F. , Dadaev, Tokhir , Berndt, Sonja I. , Wang, Ying , Couch, Fergus J. , Wolk, Alicja , Giles, Graham G. , Nguyen‐Dumont, Tú , Milne, Roger L. , Key, Tim , Stopsack, Konrad H. , Southey, Melissa C. , Wiklund, Fredrik E. , Conti, David V.

Mayo Clinic

JAMA Oncology | September 21, 2023 | Volume: 9 | Issue: 11 | Pages: 1514

10.1001/jamaoncol.2023.3482 | PMID 37733366 Get It

Importance Germline gene panel testing is recommended for men with advanced prostate cancer (PCa) or a family history of cancer. While evidence is limited for some genes currently included in panel testing, gene panels are also likely to be incomplete and missing genes that influence PCa risk and aggressive disease. Objective To identify genes associated with aggressive PCa. Design, Setting, and Participants A 2-stage exome sequencing case-only genetic association study was conducted including men of European ancestry from 18 international studies. Data analysis was performed from January 2021 to March 2023. Participants were 9185 men with aggressive PCa (including 6033 who died of PCa and 2397 with confirmed metastasis) and 8361 men with nonaggressive PCa. Exposure Sequencing data were evaluated exome-wide and in a focused investigation of 29 DNA repair pathway and cancer susceptibility genes, many of which are included on gene panels. Main Outcomes and Measures The primary study outcomes were aggressive (category T4 or both T3 and Gleason score ≥8 tumors, metastatic PCa, or PCa death) vs nonaggressive PCa (category T1 or T2 and Gleason score ≤6 tumors without known recurrence), and metastatic vs nonaggressive PCa. Results A total of 17 546 men of European ancestry were included in the analyses; mean (SD) age at diagnosis was 65.1 (9.2) years in patients with aggressive PCa and 63.7 (8.0) years in those with nonaggressive disease. The strongest evidence of association with aggressive or metastatic PCa was noted for rare deleterious variants in known PCa risk genes BRCA2 and ATM ( P ≤ 1.9 × 10 −6 ), followed by NBN ( P = 1.7 × 10 −4 ). This study found nominal evidence ( P < .05) of association with rare deleterious variants in MSH2 , XRCC2 , and MRE11A . Five other genes had evidence of greater risk (OR≥2) but carrier frequency differences between aggressive and nonaggressive PCa were not statistically significant: TP53 , RAD51D , BARD1 , GEN1 , and SLX4 . Deleterious variants in these 11 candidate genes were carried by 2.3% of patients with nonaggressive, 5.6% with aggressive, and 7.0% with metastatic PCa. Conclusions and Relevance The findings of this study provide further support for DNA repair and cancer susceptibility genes to better inform disease management in men with PCa and for extending testing to men with nonaggressive disease, as men carrying deleterious alleles in these genes are likely to develop more advanced disease.
Parvalbumin-Positive Neurons in the Globus Pallidus Externus Modulate Task-Irrelevant Behaviors to Balance Exploration and Exploitation
Kang, Shinwoo , Yang, Minsu Abel , Bruce, Robert, Song, Minryung , Bruce, Robert, Choi, Doo‐Sup , Lee, Sang Wan

Mayo Clinic

2023 Conference on Cognitive Computational Neuroscience | September 6, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.32470/ccn.2023.1450-0 Get It

Usability and feasibility of PreventS-MD web app for stroke prevention
Feigin, Valery L. , Krishnamurthi, Rita , Medvedev, Oleg N. , Merkin, Alexander, Nair, Balakrishnan, Jalili-Moghaddam, Shabnam, Barker‐Collo, Suzanne , Ratnasabapathy, Yogini , Skinner, Luke C , Sachdev, Perminder S. , Brainin, Michael , Hankey, Graeme J. , Azarpazhooh, Reza, Bhatia, Anjali , Budinčević, Hrvoje , Child, Nicholas, Chwojnicki, Kamil , Correia, Manuel, Davis, Alan , Devlin, Gerry , Demarin, Vida , Dhamija, Rajinder K. , Ding, Ding , Докова, Клара , Dudley, Makarena , Dyer, Jesse, Edmonds, Misty , Ely, Marcela , Feigin, Svetlana , Fornolles, C, Gall, Seana , Gil, Artyom , George, Ann, Haršány, Michal , Harwood, Matire, Hou, Zeng‐Guang , Ibrahim, Norlinah Mohamed, Ka‘ai, Tania , Kalra, Nidhi , Katzenellenbogen, Judith , Kang, Law Zhe, Kar, Arindam , Kazin, Vitalij, Kamenova, Saltanat , Kondybaeva, A., Lavados, Pablo M, Lee, Tsong‐Hai , Liu, Liping , Mahawish, Karim , Maluchnik, Michał , Martins, Sheila , Mavaddat, Nahal , Mehndiratta, Man Mohan, Oliver, Angela , Öztürk, Şerefnur , Patel, Nikhil, Prakash, B, Roos, Kev, Sekaran, Lakshmanan , Shamalov, N. А. , Solomon, Alina, Suwanwela, Nijasri C., Volevach, Ekaterina , Volný, Ondřej , Wan, Joyce, Withanapathirana, Katila, Welte, Tamara, Wiebers, David O. , Zaidi, Wan Asyraf Wan , Kravchenko, Michael , Barker-Collo, Suzanne , Owolabi, Mayowa , Sachdev, Perminder S , Brainin, Michael , Thrift, Amanda , Hankey, Graeme J , Katzenellenbogen, Judith M , Nair, Balakrishnan, Kravchenko, Michael , Jalili‐Moghaddam, Shabnam , Norrving, Bo , Arroll, Bruce , Thrift, Amanda G. , Abd-Allah, Foad , Akinyemi, Rufus , Bath, Philip M. , Brayne, Carol , Child, Nicholas, Farhoudi, Mehdi , Aziz, Aznida Firzah Abdul , Gabriel, Denis , Gnedovskaya, Elena V. , Harwood, Matire L. N. , Hillis, Argye Elizabeth , Hwang, Kevin O. , Ibrahim, Norlinah Mohamed , Kalra, Nidhi, Karaszewski, Bartosz , Kivipelto, Miia , Lavados, Pablo M. , Mateen, Farrah J. , Mikulík, Robert , Oliver, Angela, Patel, Nikhil, Пирадов, М. А. , Purvis, Tara L. , Reips, Ulf‐Dietrich , Rosand, Jonathan M. , Sahathevan, Ramesh , Silva, Deidre Anne De , Singh, Vinod, Srivastava, M.V. Padma , Taylor, Denise M. , Truelsen, Thomas Clement , Venketasubramanian, Narayanaswamy , Winkler, Andrea Sylvia , Wijeratne, Tissa , Wu, Teddy Y

Mayo Clinic

International Journal of Stroke | July 24, 2023 | Volume: 19 | Issue: 1 | Pages: 94-104

10.1177/17474930231190745 | PMID 37485871 Get It

Background: Most strokes and cardiovascular diseases (CVDs) are potentially preventable if their risk factors are identified and well controlled. Digital platforms, such as the PreventS-MD web app (PreventS-MD) may aid health care professionals (HCPs) in assessing and managing risk factors and promoting lifestyle changes for their patients. Methods: This is a mixed-methods cross-sectional two-phase survey using a largely positivist (quantitative and qualitative) framework. During Phase 1, a prototype of PreventS-MD was tested internationally by 59 of 69 consenting HCPs of different backgrounds, age, sex, working experience, and specialties using hypothetical data. Collected comments/suggestions from the study HCPs in Phase 1 were reviewed and implemented. In Phase 2, a near-final version of PreventS-MD was developed and tested by 58 of 72 consenting HCPs using both hypothetical and real patient (n = 10) data. Qualitative semi-structured interviews with real patients (n = 10) were conducted, and 1 month adherence to the preventive recommendations was assessed by self-reporting. The four System Usability Scale (SUS) groups of scores (0–50 unacceptable; 51–68 poor; 68–80.3 good; >80.3 excellent) were used to determine usability of PreventS-MD. Findings: Ninety-nine HCPs from 27 countries (45% from low- to middle-income countries) participated in the study, and out of them, 10 HCPs were involved in the development of PreventS before the study, and therefore were not involved in the survey. Of the remaining 89 HCPs, 69 consented to the first phase of the survey, and 59 of them completed the first phase of the survey (response rate 86%), and 58 completed the second phase of the survey (response rate 84%). The SUS scores supported good usability of the prototype (mean score = 80.2; 95% CI [77.0–84.0]) and excellent usability of the final version of PreventS-MD (mean score = 81.7; 95% CI [79.1–84.3]) in the field. Scores were not affected by the age, sex, working experience, or specialty of the HCPs. One-month follow-up of the patients confirmed the high level of satisfaction/acceptability of PreventS-MD and (100%) adherence to the recommendations. Interpretation: The PreventS-MD web app has a high level of usability, feasibility, and satisfaction by HCPs and individuals at risk of stroke/CVD. Individuals at risk of stroke/CVD demonstrated a high level of confidence and motivation in following and adhering to preventive recommendations generated by PreventS-MD.
SP11. Gene Expressions of Fgf7 and Postn in Canine Chordae Tendineae and Their Possible Relations to Tenogenesis in Chordae Tendineae and Potential Effects on Flexor Tenocyte Biology
Wan, Rou , Ren, Ye , Yu, Yinxian, Reisdorf, Ramona L., Moran, Steven L. , Zhao, Chunfeng , Gingery, Anne

Mayo Clinic

Plastic and Reconstructive Surgery - Global Open | July 21, 2023 | Volume: 11 | Issue: 5S | Pages: 126-126

10.1097/01.gox.0000938388.68998.93 Get It

A Syx-RhoA-Dia1 signaling axis regulates cell cycle progression, DNA damage, and therapy resistance in glioblastoma
Lin, Wan‐Hsin , Feathers, Ryan W. , Cooper, Lisa M. , Lewis‐Tuffin, Laura J. , Chen, Jiaxiang , Anastasiadis, Panos Z. , Sarkaria, Jann N.

Mayo Clinic

JCI Insight | July 9, 2023 | Volume: 8 | Issue: 13 | Pages: No page available

10.1172/jci.insight.157491 | PMID 37427593 Get It

Glioblastomas (GBM) are aggressive tumors that lack effective treatments. Here, we show that the Rho family guanine nucleotide exchange factor Syx promotes GBM cell growth both in vitro and in orthotopic xenografts derived from patients with GBM. Growth defects upon Syx depletion are attributed to prolonged mitosis, increased DNA damage, G2/M cell cycle arrest, and cell apoptosis, mediated by altered mRNA and protein expression of various cell cycle regulators. These effects are phenocopied by depletion of the Rho downstream effector Dia1 and are due, at least in part, to increased phosphorylation, cytoplasmic retention, and reduced activity of the YAP/TAZ transcriptional coactivators. Furthermore, targeting Syx signaling cooperates with radiation treatment and temozolomide (TMZ) to decrease viability in GBM cells, irrespective of their inherent response to TMZ. The data indicate that a Syx-RhoA-Dia1-YAP/TAZ signaling axis regulates cell cycle progression, DNA damage, and therapy resistance in GBM and argue for its targeting for cancer treatment.
DIPNECH: pragmatic approach, uncertainties, notable associations, and a proposal for an improved definition
Samhouri, Bilal F. , Hálfdánarson, Þorvarður R. , Koo, Chi Wan , McCarthy, Cormac , Yi, Eunhee S. , Thomas, Charles F., Ryu, Jay H. , Halfdanarson, Thorvardur R , Ryu, Jay H

Mayo Clinic

Endocrine-Related Cancer | July 6, 2023 | Volume: 30 | Issue: 10 | Pages: No page available

10.1530/erc-23-0051 | PMID 37410394 Get It

Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH) is a rare, but increasingly recognized entity that primarily affects middle-aged and elderly women. It is characterized by abnormal proliferation of pulmonary neuroendocrine cells (PNECs) and is considered a preinvasive lesion for carcinoid tumorlets/tumors. Sometimes, DIPNECH is accompanied by constrictive bronchiolitis which usually manifests as chronic cough and/or dyspnea, along with airflow limitation on spirometry. The telltale imaging sign of DIPNECH is the presence of multiple noncalcified pulmonary nodules and mosaic attenuation on CT. However, these clinico-radiologic features of DIPNECH are characteristic but nonspecific; thus, histopathologic confirmation is usually necessary. DIPNECH has an indolent course and only rarely leads to respiratory failure or death; progression to overt neuroendocrine tumor (carcinoid) of the lung occurs in a minority of patients. Of available therapies, somatostatin analogs and mechanistic target of rapamycin inhibitors are the most promising. In this review, we provide an update regarding the diagnosis and management of DIPNECH and describe critical gaps in our understanding of this entity, including the central terms ‘diffuse’ and ‘idiopathic.’ We also summarize the inconsistencies in definitions employed by recent studies and discuss the pitfalls of the DIPNECH definitions proposed by the World Health Organization in 2021. In this context, we propose an objective and reproducible radio-pathologic case definition intended for implementation in the research realm and seeks to enhance homogeneity across cohorts. Furthermore, we discuss aspects of PNECs biology which suggest that PNEC hyperplasia may contribute to the pathogenesis of phenotypes of lung disease aside from constrictive bronchiolitis and carcinoid tumorlets/tumors. Finally, we steer attention to some of the most pressing and impactful research questions awaiting to be unraveled.
Factors Affecting C5 Viability and Demographic Variability in Two Brachial Plexus Centers
Zelenski, Nicole A. , Joslyn, Nichole A., Lee, Ying-Hsuan, Chuang, David Chwei‐Chin , Lu, Johnny Chuieng‐Yi , Chang, Tommy Nai‐Jen , Spinner, Robert J. , Lee, Ying Hsuan, Bishop, Allen T. , Shin, Alexander Y.

Mayo Clinic

Plastic and Reconstructive Surgery - Global Open | June 20, 2023 | Volume: 11 | Issue: 6 | Pages: e5073

10.1097/gox.0000000000005073 | PMID 37456133 Get It

Background: Complete brachial plexus injuries are devastating injuries. A viable C5 spinal nerve can offer additional sources of axons and alter surgical treatment. We aimed to determine factors that portend C5 nerve root avulsion. Methods: A retrospective study of 200 consecutive patients with complete brachial plexus injuries at two international centers (Mayo Clinic in the United States and Chang Gung Memorial Hospital in Taiwan) was performed. Demographic information, concomitant injuries, mechanism, and details of the injury were determined, and kinetic energy (KE) and Injury Severity Score were calculated. C5 nerve root was evaluated by preoperative imaging, intraoperative exploration, and/or intraoperative neuromonitoring. A spinal nerve was considered viable if it was grafted during surgery. Results: Complete five-nerve root avulsions of the brachial plexus were present in 62% of US and 43% of Taiwanese patients, which was significantly different. Increasing age, the time from injury to surgery, weight, body mass index of patient, motor vehicle accident, KE, Injury Severity Score, and presence of vascular injury significantly increased the risk of C5 avulsion. Motorcycle (≤150cc) or bicycle accident decreased the risk of avulsion. Significant differences were found between demographic variables between the two institutions: age of injury, body mass index, time to surgery, vehicle type, speed of injury, KE, Injury Severity Score, and presence of vascular injury. Conclusions: The rate of complete avulsion injury was high in both centers. Although there are a number of demographic differences between the United States and Taiwan, overall the KE of the accident increased the risk of C5 avulsion.
Astrocyte activities in the external globus pallidus regulate action-selection strategies in reward-seeking behaviors
Kang, Shinwoo , Hong, Sa‐Ik , Kang, Seungwoo , Song, Minryung , Yang, Minsu Abel , Essa, Hesham , Lee, Jeyeon , Bruce, Robert A., Lee, Sang Wan , Choi, Doo-Sup , Song, Minryung , Yang, Minsu Abel , Baker, Matthew , Choi, Doo‐Sup

Mayo Clinic

Science Advances | June 16, 2023 | Volume: 9 | Issue: 24 | Pages: No page available

10.1126/sciadv.adh9239 | PMID 37327345 Get It

An imbalance in goal-directed and habitual behavioral control is a hallmark of decision-making–related disorders, including addiction. Although external globus pallidus (GPe) is critical for action selection, which harbors enriched astrocytes, the role of GPe astrocytes involved in action-selection strategies remained unknown. Using in vivo calcium signaling with fiber photometry, we found substantially attenuated GPe astrocytic activity during habitual learning compared to goal-directed learning. The support vector machine analysis predicted the behavioral outcomes. Chemogenetic activation of the astrocytes or inhibition of GPe pan-neuronal activities facilitates the transition from habit to goal-directed reward-seeking behavior. Next, we found increased astrocyte-specific GABA (γ-aminobutyric acid) transporter type 3 (GAT3) messenger RNA expression during habit learning. Notably, the pharmacological inhibition of GAT3 occluded astrocyte activation–induced transition from habitual to goal-directed behavior. On the other hand, attentional stimuli shifted the habit to goal-directed behaviors. Our findings suggest that the GPe astrocytes regulate the action selection strategy and behavioral flexibility.